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Thromboembolism is a serious and common complication of
the nephrotic syndrome [II. It is rarely seen in childhood in the
absence of a primary disease such as the steroid—responsive
nephrotic syndrome (SRNS), diabetes or hyperlipidemia. Dur-
ing the treatment of thrombotic episodes in nephrotic children
with heparin, we formed the impression that the dose required
to achieve anticoagulation was greater than in other patients, an
observation also reported by Fischer et al [2]. While most
children are effectively anticoagulated with heparin doses of 25
U/kg/hr. some nephrotic children required as much as 60
U/kg/hr. We therefore studied the anticoagulant effect of
heparin in vitro on plasma from children with the SRNS, normal
children and adults, and children with other renal diseases. We
observed that in vitro, heparin sensitivity is reduced in the
SRNS and declines with age in healthy individuals. We also
report the results of investigations to identify the mechanisms
responsible for the diminished heparin sensitivity in SRNS.
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Methods
Patients
The following groups of patients were studied:
Children with steroid responsive nephrotic syndrome. SRNS
was diagnosed by standard criteria [3] in 16 children (13 boys, 3
girls) aged three to 17 years. In addition, two children (a boy
aged 10 years and a girl aged 3 years) with steroid—resistant
nephrotic syndrome and renal biopsy findings of focal segmen-
tal glomerulosclerosis were studied. All patients were in relapse
when investigated (3+ proteinuria [Albustix] for 3 or more
consecutive days), and most were studied before corticosteroid
therapy was restarted.
Normal children. Plasma was obtained from 10 normal chil-
dren aged 12 to 14 years (3 boys, 7 girls) from whom blood was
taken as part of the Chard study of normal growth and adoles-
cence approved by the Ethical Committee of the Hospital for
Sick Children, Great Ormond Street, London.
Children with other renal diseases. Thirteen children (6 boys,
7 girls) aged six months to 15 years, with a variety of other renal
diseases who were not nephrotic (plasma albumin >25 g/liter)
were also studied. Their primary renal diseases were:
Henoch—SchOnlein purpura, hemolytic—uremic syndrome, Bart-
ter's syndrome, focal segmental glomerulosclerosis, mesangial
proliferative glomerulonephritis, bilateral renal dysplasia, pos-
terior urethral valves, and vesico-ureteric reflux.
Normal adults. Twenty—two healthy hospital and laboratory
personnel (14 males, 8 females) aged 18 to 60 years were
studied.
Elderly adults. Twenty otherwise healthy adults (4 males, 16
females) aged 60 to 85 years, with minor osteoarthritis, attend-
ing a rheumatology clinic at Whipps Cross Hospital were
studied.
Adults with hyperlipidemia. Four adult males aged 25 to 51
years with Type II hyperlipidemia were studied. Their plasma
cholesterol concentration ranged from 5 to 7 mmollliter and
their triglyceride concentration from 1.3 to 3.3 mmoles/liter.
Methods
Collection of blood. Venous blood was collected through a 23
gauge butterfly needle and immediately transferred to a plastic
tube containing 1/10th volume of 3.8% trisodium citrate. The
sample was centrifuged at 1,000 g for 15 minutes, and the
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syndrome. The in vitro heparin sensitivity of 18 nephrotic children was
compared with that of 10 normal children and 13 children with other
renal diseases, The influence of age on the heparin sensitivity of 52
normal subjects (aged 12 to 85 years) was also studied. The heparin
sensitivity was calculated from the dose—response curve obtained when
increasing amounts of heparin were added to plasma and the kaolin
partial thromboplastin time (KPTT) was measured. There was a
significantly—reduced heparin sensitivity in nephrotic children com-
pared to the control children and a progressive decline in heparin
sensitivity with age. In the nephrotic syndrome heparin—sensitivity
correlated with albumin and triglyceride concentrations but not with
antithrombin III, platelet factor 4, cholesterol, fibrinogen, heparin
cofactor II or histidine—rich glycoprotein. Addition of exogenous albu-
min did not restore the heparin sensitivity of nephrotic plasma. Four
patients with Type II hyperlipidemia had a normal sensitivity to
heparin. The decreased sensitivity to heparin thus does not appear to be
a consequence of the nephrotic state, and may be a reflection of an
underlying disturbance of charged macromolecules in steroid—
responsive nephrotic syndrome.
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Fig. 2. Influence of heparin on the KP1T of a normal child (z.) and a
child with SRNS (•). Hepann sensitivity is defined as the slope of the
dose—response relationship. The total amount of heparin required to
obtain a KPTT of 100 sec is calculated from point a. The heparin
neutralizing activity is calculated from point b.
plasma was then removed and stored at —40°C or —70°C until
required.
In—vitro anticoagulant effect of heparin. In initial studies, the
in vitro effect of heparin on the kaolin partial thromboplastin
time (KPTF) [4] was assessed as follows: after determination of
the baseline KPTT, 50 mU of heparin (heparin sodium BP
[mucous] Pabyrn [1,000 U/mI]) in 10 .d of isotonic saline was
added to 0.8 ml of citrated plasma. One hundred d of the
mixture was removed and its KPTT was determined. A further
50 mU of heparin was added to the residual plasma giving a
heparin concentration of 132 U/liter, and a further 100 1d of the
mixture removed for the measurement of the KPT1'. The
sequence was continued until the KPTT was above 100 sec-
onds. A dose—response curve was then plotted relating the
KP'l'T to the heparin concentration (Fig. 1). In subsequent
studies, in order to reduce the volume of plasma required, 0.5
ml of plasma was used. In cases in which the KPTT had not
reached 100 seconds, with a heparin concentration of 595
U/liter, the amount of heparin required was estimated from the
slope of the linear regression analysis. From this dose—response
curve, three parameters were obtained (Fig. 2): Heparin sensi-
tivity was defined as the slope (calculated by linear regression
Other measurements
Albumin was measured by single radial gel—diffusion [5].
Triglycerides and cholesterol were measured by commercial-
ly—supplied enzymatic methods (triglycerides: Human Biochemi-
ca und Diagnostica, FRG; cholesterol: Abbott Laboratories,
UK). Antithrombin III (ATIII) was measured by radial
immunodiffusion using NOR-Partigen' Antithrombin III plates
(Boehring Institute, FRG), and in four patients the results were
confirmed by a functional colorimetric assay (Diacrom ATIII-
Weilcome, UK). Platelet factor 4 (PF4) was determined using a
platelet factor 4 radioimmunoassay diagnostic kit (Abbott Lab-
oratories). Fibrinogen was measured by the technique of Clauss
[6]. Histidine—rich glycoprotein (HRG) was measured by radio-
immunoassay (Dr. Joan Dawes, Edinburgh).
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Fig. 1. Influence of heparin on the KP7T of normal children
children with SRNS (—•). KPTF is expressed as
the percentage increase above the initial value.
analysis) of the KPTT/heparin dose—response curve after an
0 200 400 600 800 initial inflection of more than 15% above the basal KPTT, and
results were expressed in sec U . liter. The intercept of the
KPTr/heparin slope and the baseline was used to calculate the
heparin neutralizing activity, defined as the amount of heparin
required before prolongation of the KPTT, was observed (point
b in Fig. 2). The point at which the KPTT/heparin regression
line reached 100 seconds was used to derive the total heparin
requirement for anticoagulation (point a in Fig. 2).
In initial studies, the anticoagulant effect of heparin was also
determined using the thrombin time. As the results were similar
to those obtained using the KPTT, only the latter was used in
subsequent studies. In three children with SRNS, heparin
sensitivity was also measured after adjustment of the plasma
albumin concentration to 40 g/liter by the addition of human
serum albumin (Sigma, UK, A 1887).
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Fig. 3. Total requirement of heparin to obtain
a KPTT of 100 sec. Horizontal bars indicate
mean SD.
Hepann cofactor II was determined using a functional
colorimetric assay as described by Sie et al [71. To remove
contaminating heparin in the dermatan sulphate reagent
(chondroitin sulphate B, Sigma), the preparation was treated
with nitrous acid and then dialyzed for four hours against
Tris-HCI 0.05 M, pH 8.0, and then overnight against NaCI 0.15
M, Tris-HCI 0.02 M, pH 7.4, and polyethyleneglycol 1%.
Statistical methods
Correlation coefficients, slopes and intercepts were derived
from linear regression analysis. Means were compared by
Student's t-test.
Results
Total heparin requirement for anticoagulation
The mean concentration of heparin required to achieve
anticoagulation (KPTI'= 100 sec) of plasma from children with
SRNS was 564±378 (SD) U/liter, significantly more than that
required in normal children (247±46 U/liter, P<0.02), or in
children with other renal diseases (209± 39 U/liter, P<0.01)
(Fig. 3). Some adults over 60 years of age also had greater
heparin requirements than normal children, but the mean was
not significantly different (332±209 U/liter). The increased
heparin requirement of SRNS children was not explained by
any difference in the initial KPTT (SRNS children: 38±7.3 see,
control children: 40±1.6 see, children with other renal diseases:
38±2.6 see, adults aged 18 to 60 years: 39±5.6 see, adults over
60 years: 44±6.0 see).
Heparin sensitivity
Children with SRNS showed significantly—reduced heparin
sensitivity with a mean slope of the KPYF/heparin dose—re-
sponse of 0.25 0.15 (SD) see . U liter compared to that of
normal children (0.57 0.19 see• U liter, P<0.00l), and
children with other renal diseases (0.42 0.12 sec . U liter,
P<0.01) (Fig. 4). There was a decline in heparin sensitivity with
age with adults above 60 years, having a slope of 0.31 0.19
sec• U liter, which was significantly different from that of
normal children (P<0.0l) (Fig. 4).
Heparin neutralizing activity
There was no significant difference between the amount of
heparin required to achieve an initial prolongation of the KPTT
in the children with SRNS (mean 139±85 [SD] U/liter) and the
control children (119±43 U/liter), nor were there any significant
differences between the other groups studied (Fig. 5).
Factors affecting the heparin activity
No differences were observed between those patients receiv-
ing corticosteroids and those not on treatment. The plasma
concentrations of albumin, triglycerides, cholesterol, ATIII,
PF4, heparin cofactor II, and fibrinogen are shown in Table I.
ATIII, albumin, and HRG were significantly lower in SRNS
children than in normal children and cholesterol and
triglycerides significantly higher. However, within the SRNS
patients only albumin and cholesterol concentrations were
significantly correlated with heparin sensitivity, and no corre-
lation between heparin sensitivity and ATIII concentration was
observed (r=0.04) (Fig. 6). When the albumin concentration of
SRNS plasma was adjusted to 40 g/liter by the addition of
albumin in vitro, no significant change in heparin sensitivity was
observed (mean slope before the addition of albumin 0.23
(SD) sec - U liter, after the addition of albumin 0.21±0.13
sec U' liter).
Four adults with hyperlipidemia had a mean heparin sensi-
tivity of 0.50 0.13 sec . U' - liter, not significantly different
from the normal adults.
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Discussion
We have shown that significantly more heparin is required to
prolong the KPTI'in plasma from children with the SRNS than
in plasma from normal children or those with other renal
diseases. This is due to a reduced sensitivity to hepann rather
than to an increased heparin neutralizing—activity. These in
vitro observations confirm the clinical impression that heparin
requirements are increased in SRNS. This observation has both
theoretical and clinical implications. We have also shown that
heparin sensitivity declines with age.
The mechanisms of action of heparin are complex and are
N
Controls
mean SD
SR
N
NS Children
mean SD r
Albumin g/iiter 10 38.9 6.8 17 21.6 15" 0.67"
Triglycerides mmol/Iiter 10 0.8 0.4 12 2.1 1.3" 0.61
Cholesterol mmoi/liter 10 3.4 0.5 11 7.2 2.5c —0.45
Antithrombin III U/mi 10 0.89 0.03 9 0.67 0.l8c 0.04
Platelet factor 4 mg/mi 10 1.0 0.4 13 1.4 1.1 —0.43
Heparin cofactor II U/mi 7 1.03 0.14 8 0.99 0.17 0.10
Histidine—rich glyco-
protein pg/ml 6111 13 17 82 28k' 0.21
Fibrinogen g/liter not measured 13 2.9 0.7 0.05
influenced by many factors. Heparin exerts its anticoagulant
action by complexing with ATIII and increasing the rate at
which ATIII inactivates thrombin as well as the factors IXa,
Xa, XIa, and XIIa [8]. The anionic glycosaminoglycans (GAGs)
heparin, heparan sulphate, dermatan sulphate and chondroitin
sulphate are naturally occurring constituents of the vascular
endothelium [9, 10], basement membranes [111, and plasma [12,
13], and probably exert a local anticoagulant effect at these sites
[14]. In addition to its action on ATIII, heparin also accelerates
the rate at which heparin cofactor II inactivates thrombin [15].
However, endogenous dermatan sulphate may be more impor-
tant in the action of the heparin cofactor II than heparin [16].
The anticoagulant effect of heparin can be neutralized by
several proteins normally present either in the plasma or
released from intracellular sites. These include PF4 [17], /3-
thromboglobulin [18] and histidine—rich glycoprotein [19].
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Many other plasma constituents may bind to or interact with
hepann, including lipoproteins, lipids and other plasma proteins
[20].
In order to investigate the reduced heparin sensitivity in
SRNS, we measured several of the factors known to influence
heparin activity. The plasma concentration of ATIII was signif-
icantly lower in the children with SRNS than in the controls.
However there was no correlation between the level of ATIII
and heparin sensitivity; some patients with the lowest heparin
sensitivity had normal levels of ATIII, and conversely other
patients with reduced ATIII had normal heparin sensitivity.
HRG was a heparin neutralizing factor, but was reduced in
nephrotic patients. Platelet factor 4 is also a heparin neutraliz-
ing factor and, in view of the platelet hyperaggregabiity in
SRNS [21], PF4 may have been released either in vivo or during
the preparation of the plasma. However we found no difference
between the PF4 levels of the SRNS patients and the controls,
although the levels in both groups were high due to our use of
citrate as anticoagulant rather than platelet release—inhibiting
agents such as EDTA, PGE and indomethacin. Heparin cofac-
tor II is another plasma protein which may influence the activity
of heparin, but the levels of heparin cofactor II were normal in
the children we studied.
There was a significant correlation between the heparin
sensitivity and the plasma albumin concentration, as well as a
negative correlation with triglyceride concentration. However,
correction of the reduced albumin in SRNS plasma by the
addition of exogenous albumin had no effect on heparin sensi-
tivity, indicating that hypoalbuminemia itself is not the expla-
nation for the reduced heparin sensitivity. It may be, though,
that the hypoalbuminemia in vivo sets in train a series of events
conducive to heparin resistance which are not correctable by
the addition of albumin in vitro, and the effect of albumin
infusion was not examined, nor were patients with other causes
of hypoalbuminemia studied. The lipid abnormality in the
nephrotic syndrome is unlikely to be responsible, for patients
with type II hyperlipidemia had normal heparin sensitivity. The
hepann sensitivity, albumin and triglyceride concentrations
may therefore simply be independent consequences of the
nephrotic state.
In addition to those which we have measured, hepann
activity may be influenced by many other factors. The levels of
endogenous GAGs, heparan sulphate, chondroitin sulphate and
dermatan sulphate may alter the distribution, binding and
availability of exogenous heparin [22]. In view of the highly
anionic nature of heparin, it is possible that it may bind to or
interact with several other cationic proteins, including those
released from neutrophils [23], eosinophils [24], and platelets
[25], as well as exogenous cationic proteins such as protamine
and polylysine [26]. We have previously reported a reduction of
surface charge on red blood cells and platelets in SRNS and
suggested that this is due to the neutralization of cell surface
charge by an adherent cationic factor [27]. It is possible that the
same factor which binds to and neutralizes the sialic acid groups
on the red blood cells and platelets would also bind to and
neutralize the highly anionic heparin. If so, it might have been
expected that the heparin neutralizing activity rather than the
sensitivity to the anticoagulant effect of heparin would have
been most affected, whereas the converse was found in the
present study. Nevertheless, decreased heparin sensitivity and
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reduced cell surface—charge may reflect similar phenomena,
and, as anionic GAGs are largely responsible for the negative
charge on the glomerular capillary wall [28], the same factor
might also be responsible for the reduction of glomerular
anionic charge believed to be present in SRNS [29, 30].
The reduced heparin sensitivity observed with increasing age
is of interest, and is surprising in view of the clinical reports of
increased sensitivity to heparin therapy in the elderly [31, 32].
Thrombotic disease rarely occurs in childhood, except in asso-
ciation with an underlying disorder such as SRNS, diabetes or
hyperlipidemia. The incidence of thrombosis increases progres-
sively with age. If the observed reduction of heparin sensitivity
with increasing age reflects a decline in the natural anticoagu-
lant mechanisms, it may offer an explanation for the tendency
to thrombosis in the elderly.
The finding of reduced heparin sensitivity in SRNS and in the
elderly suggests that the heparin dosage in these patients should
be adjusted according to its observed anticoagulant effect rather
than simply calculated from the body weight.
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